Core Points - The company has obtained a total of 4 domestic patent certificates, including 2 invention patents and 2 design patents, as well as 2 foreign patents, 3 computer software copyright registration certificates, and 1 Class I medical device filing certificate from July 1, 2025, to September 30, 2025 [1][2][3] Group 1: Patent Certificates - The acquisition of the patents reflects the company's core technology and will enhance its intellectual property protection system, promoting technological innovation and improving core competitiveness [1][2] - The recent patent acquisitions are not expected to have a significant impact on the company's short-term operations [1][2] Group 2: Computer Software Copyright - The obtained computer software copyright registration certificates will help enhance the company's core competitiveness and support the establishment of a continuous innovation mechanism [2] Group 3: Medical Device Filing - The Class I medical device filing certificate will diversify the company's product offerings and meet market demand, thereby strengthening its core competitiveness [3] - The sales performance of the products post-launch will depend on future market promotion efforts, and the company cannot currently predict the specific impact on future revenue [3]

关于取得专利证书、软件著作权登记证书 及医疗器械备案凭证的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱威科技股份有限公司（以下简称"公司"）及其子公司自 2025 年 7 月 1 日起至 2025 年 9 月 30 日共取得境内专利证书 4 项，其中发明专利 2 项、外观 设计专利 2 项；取得境外专利 2 项；取得计算机软件著作权登记证书 3 项；取 得第一类医疗器械备案凭证 1 项。具体情况如下： 一、专利证书 | 序 | 专利名称 | 专利号 | 专利权人 | 申请日期 | 专利 | 取得 | 授权日期 | | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | | 类别 | 方式 | | | 1 | 一种医疗检验用 废液收集处理装 | ZL202510065768.5 | 爱威科技 | 2025/01/16 | 发明 | 自主 研发 | 2025/04/29 | | | 置 | | | | | | | | 2 | 一种拭子采样 ...

证券日报网讯9月24日晚间，爱威科技发布公告称，近日，公司已完成工商变更登记和章程备案手续， 并取得了湖南湘江新区管理委员会行政审批服务局换发的《营业执照》。 ...

证券代码：688067 证券简称：爱威科技 公告编号：2025-040 爱威科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱威科技股份有限公司（以下简称"公司"）分别于 2025 年 8 月 28 日召开 第五届董事会第五次会议、2025 年 9 月 17 日召开 2025 年第一次临时股东大会， 审议通过了《关于变更经营范围、取消监事会及修订<公司章程>并办理相应工商 变更登记的议案》,具体内容详见公司于 2025 年 8 月 29 日在上海证券交易所网 站（www.sse.com.cn）披露的《关于变更经营范围、取消监事会、修订<公司章 程>、制定及修订部分治理制度并办理相应工商变更登记的公告》。 近日，公司已完成工商变更登记和章程备案手续，并取得了湖南湘江新区管 理委员会行政审批服务局换发的《营业执照》，变更后的具体登记信息如下： 统一社会信用代码：914301001838986849 注册资本：陆仟捌佰万元整 类型：股份有限公司（上市、自然人投资或控股） ...

Group 1 - The core point of the news is that Aiwei Technology's stock has experienced a decline of 5.25% on September 23, with a total market value of 1.645 billion yuan and a cumulative drop of 3.44% over three consecutive days [1] - Aiwei Technology, established on March 16, 2000, and listed on June 16, 2021, specializes in the research, production, sales, and service of medical clinical testing analysis instruments and related in vitro diagnostic reagents and medical consumables [1] - The revenue composition of Aiwei Technology includes reagents at 45.63%, instruments at 34.53%, consumables at 17.56%, and others at 2.28% [1] Group 2 - According to data, the top circulating shareholder of Aiwei Technology is the Nuoan Multi-Strategy Mixed A Fund (320016), which entered the top ten shareholders in the second quarter with 477,400 shares, accounting for 0.7% of circulating shares [2] - The estimated floating loss for the Nuoan Multi-Strategy Mixed A Fund today is approximately 639,700 yuan, with a floating loss of 434,400 yuan during the three-day decline [2] - The Nuoan Multi-Strategy Mixed A Fund has a total scale of 1.399 billion yuan and has achieved a return of 57.56% this year, ranking 694 out of 8,172 in its category [2] Group 3 - The fund managers of Nuoan Multi-Strategy Mixed A are Kong Xianzheng and Wang Haichang, with Kong having a tenure of 4 years and 302 days and a best fund return of 72.6% during his tenure [3] - Wang Haichang has a tenure of 3 years and 64 days, with a best fund return of 60.45% during his tenure [3]

Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 18.892 billion yuan, while the Sci-Tech Innovation Board saw a net inflow of 731 million yuan [1] - A total of 217 stocks on the Sci-Tech Innovation Board had net inflows, while 370 stocks had net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 363 stocks rose, with two stocks, Honglida and Zhongke Lanyun, hitting the daily limit, while 215 stocks declined [1] - The top three stocks with the highest net inflow of funds were Haiguang Information (1.264 billion yuan), SMIC (508 million yuan), and Chipone (483 million yuan) [1][2] Continuous Fund Flow - There are 44 stocks with continuous net inflows for more than three trading days, with Cambrian leading at 24 consecutive days of inflow [2] - Conversely, 179 stocks experienced continuous net outflows, with Naike Equipment showing the longest streak at 17 consecutive days [2] Top Fund Inflows - The top stocks by net inflow include: - Haiguang Information: 1263.65 million yuan, with a flow rate of 6.95% and a price increase of 10.70% [2] - SMIC: 507.74 million yuan, with a flow rate of 2.56% and a price increase of 6.25% [2] - Chipone: 483.24 million yuan, with a flow rate of 5.98% and a price increase of 17.34% [2] Notable Outflows - The stock with the highest net outflow was Borui Pharmaceutical, which saw a decline of 13.15% and a net outflow of 367 million yuan [1] - Other notable outflows included Dekeli and Juguang Technology, with net outflows of 235 million yuan and 184 million yuan, respectively [1]

证券代码：688067 证券简称：爱威科技 公告编号：2025-039 爱威科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 2、召集和主持情况：本次会议由公司董事会召集；现场会议由公司董事长丁建文先生主持。 （五）公司董事和董事会秘书的出席情况 1、公司在任董事7人，以现场结合通讯方式出席7人； （一）非累积投票议案 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东大会主持情况等。 1、本次会议表决采取现场投票和网络投票相结合的方式，表决程序符合《公司法》和《公司章程》的 规定。 1、议案名称：《关于变更经营范围、取消监事会、修订〈公司章程〉并办理相应工商变更登记的议 案》 审议结果：通过 表决情况： ■ 2、议案名称：《关于修订公司部分治理制度的议案》 审议结果：通过 （一）股东大会召开的时 ...

湖南启元律师事务所 HUNAN QIYUAN LAW FIRM 20410007 湖南省长沙市 芙蓉区建湘路 393 号世茂环球金融中心 63 层 Tel：86-731-82953777 Fax：86-731-82953779 http://www.qiyuan.com 《上市公司股东会规则》（以下简称"《股东会规则》"）等中国现行法律、法规、 规章和规范性文件以及《爱威科技股份有限公司章程》（以下简称"《公司章程》"） 的相关规定，出具本法律意见书。 为出具本法律意见书，本所指派律师列席了本次股东大会，按照律师行业公 认的业务标准、道德规范和勤勉尽责精神，对本次股东大会进行了现场见证，并 核查和验证了公司提供的与本次股东大会有关的文件、资料和事实。 本所出具本法律意见书是基于公司向本所保证：公司已向本所提供了为出具 本法律意见书所必需的资料和信息，一切足以影响本法律意见书的事实和资料均 已向本所披露；公司向本所提供的所有资料和信息均真实、准确、完整，不存在 任何虚假记载、误导性陈述或重大遗漏，所有资料上的签字和/或印章均是真实、 有效的，有关副本或复印件与正本或原件一致。 本法律意见书仅根据《股东大会规则》 ...

证券代码：688067 证券简称：爱威科技 公告编号：2025-039 爱威科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 17 日 （二） 股东大会召开的地点：湖南省长沙市岳麓区学士街道茯苓路 26 号公司 319 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 1、公司在任董事7人，以现场结合通讯方式出席7人； 2、 公司在任监事 3 人，出席 3 人； 3、董事会秘书袁绘杰出席了本次会议，公司其他高级管理人员列席了本次会议。 二、 议案审议情况 （一） 非累积投票议案 1、 议案名称：《关于变更经营范围、取消监事会、修订<公司章程>并办理相应 工商变更登记的议案》 | 1、出席会议的股东和代理人人数 | 35 | | --- | --- | | 普通股股东人数 | 35 | | 2、出席 ...

Group 1 - The core point of the announcement is the election of Lin Changqing as the employee representative director of the fifth board of directors of Aiwei Technology Co., Ltd. [1][2] - Lin Changqing was previously a non-employee director and now meets the qualifications required by the Company Law and the company's articles of association to serve as an employee representative director [2][5] - The election was conducted in accordance with relevant laws and regulations, ensuring that the number of employee representatives does not exceed half of the total number of directors [2][5] Group 2 - Aiwei Technology Co., Ltd. announced a voluntary disclosure regarding the establishment of a holding subsidiary, Hunan Aiwei Optical Technology Co., Ltd. [6][7] - The total registered capital of Aiwei Optical is RMB 10 million, with Aiwei Technology contributing RMB 6 million (60%) and Changsha Kudan Technology Co., Ltd. contributing RMB 4 million (40%) in intellectual property [7][10] - This investment aligns with the company's strategic development plan and aims to enhance the security and stability of the supply chain while improving the core technological competitiveness of the company's products [8][13] Group 3 - The establishment of Aiwei Optical is intended to break through the technical supply barriers of high-end medical microscope core optical components, ensuring the independent control and domestic substitution of key optical technologies [13] - The funding for this investment comes from the company's own funds and will not adversely affect the company's normal operations or financial status [13][14] - Aiwei Optical has just been established, and its business operations have not yet commenced, so it is not expected to have a significant impact on the company's current year performance [13]